Scroll down to learn more

Cancer immunotherapy activates T cells and B cells that target specific tumor antigens1-3

The activated immune system is primed to recognize tumor antigens expressed by each patient's unique and frequently changing population of cancer cells1

Some activated T cells kill tumor cells directly or indirectly1

Some activated T cells activate B cells, which become antibody-producing plasma cells1

Learn more by watching Immunotherapy Is Tumor-Specific (2:10)

Immunotherapy Is Tumor-Specific

 
Scroll down to learn more

Cancer immunotherapy treatment is designed to support the immune system's ability to adapt its attack over time 1,3-6

Each patient's population of tumor cells mutates over
time, which may result in resistance to traditional
anticancer therapies1

When a tumor cell is killed, additional antigens are released, stimulating activation of new populations of
T cells and B cells that recognize tumor antigens1,2,4,5

This can result in an expanding cascade of immune cells that is able to recognize cancer cells bearing a variety of tumor antigens as the tumor mutates over time3-6

Learn more by watching Immunotherapy Is Designed to Support Immune System Adaptability (2:43)

Immunotherapy Is Designed to Support Immune System Adaptability

 
Scroll down to learn more
Immunotherapy for cancer stimulates immunologic memory, which may lead to a prolonged anti-tumor response1,7-8

Some activated immune cells become
memory cells, which remain primed to stimulate an anticancer immune
response when tumor cells bearing
target antigens are encountered within
the body1,7,8

Learn more by watching
Immunotherapy Empowers a
Durable Immune Response
(2:16)

Immunotherapy Empowers a Durable Immune Response

 

Learn More About the Immune System and Cancer

References

  1. Murphy K, Travers P, Walport M, eds. Janeway's Immunobiology. 7th ed. Garland Science, Taylor & Frances Group, LLC.
    New York, NY: 2008.
  2. Namm JP, Li Q, Lao X, et al. J Surg Oncol. 2012;105(4):431-435.
  3. Sharma P, Wagner K, Wolchok JD, Allison JP. Nat Rev Cancer. 2011;11(11):805-812.
  4. Ribas A, Butterfield LH, Glaspy JA, Economou JS. J Clin Oncol. 2003;21(12):2415-2432.
  5. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. CA Cancer J Clin. 2012;62(5):309-335.
  6. Disis ML, Strickler JH, Wallace D, et al. J Clin Oncol. 2008;26(suppl):(May 20 suppl; abstr 3015).
  7. Klebanoff CA, Gattinoni L, Restifo NP. Immunol Rev. 2006;211:214-224.
  8. Mullins DW, Sheasley SL, Ream RM, Bullock TNJ, Fu Y-X, Engelhard VH. J Exp Med. 2003;198(7):1023-1034.